Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study

The percentage of patients with a rapid onset of durable response within 17 days ranged from 42.9% to 46.2% in the nipocalimab groups vs 14.3% in the placebo group (eFigure 7); however, comparison with the placebo group did not reach statistical significance for any nipocalimab group ( p ≥ 0.103).

also in 111,027 other papers